Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
6 Web-based Lawful Administrations: Extensive Surveys and Elements - 2Skeleton of famed musketeer possibly found in Dutch church
- 3Parents speak out as 4-year-old fights button battery injury in intensive care unit
- 4A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- 5Blue Origin's next space tourism flight will break new ground for people with disabilities
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- One of the best meteor showers of the year peaks at the worst possible time this week
- Extraordinary Guinness World Records That Will Astound You
- Rediscovering Experience Through Excursions: Individual Travel Stories
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- Favored Vehicle for Seniors: Make Your Determination
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Renewables cover over 50% of German electricity consumption in Q1
